REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy ...
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
Prior to Prometheus, Mr. Stenhouse spent over 25 years at AbbVie, most recently serving as Vice President of U.S. Immunology. In this capacity, Mr. Stenhouse oversaw U.S. sales and marketing teams for ...
As most advisors are well aware, high stock prices have pushed down the market’s dividend yield. Barron’s ran a screen for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback